REGENXBIO (RGNX) Stock Price, News & Analysis

Company Overview

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Key Stats

• Today's Range: $8.57 to $9.23
• 50-Day Range: $7.46 to $10.20
• 52-Week Range: $5.03 to $13.48
• Volume: 492,810 shs
• Average Volume: 975,455 shs
• Market Capitalization: $461.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.38
• Consensus Rating: Moderate Buy

REGENXBIO Stock Analysis - MarketRank™

REGENXBIO scored higher than 85% of companies evaluated by MarketBeat, and ranked 227th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

REGENXBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

REGENXBIO has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for REGENXBIO are expected to grow in the coming year, from ($4.84) to ($1.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of REGENXBIO is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of REGENXBIO is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

REGENXBIO has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.44% of the float of REGENXBIO has been sold short.

Short Interest Ratio / Days to Cover

REGENXBIO has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in REGENXBIO has recently decreased by 11.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

REGENXBIO does not currently pay a dividend.

Dividend Growth

REGENXBIO does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.82

Percentage of Shares Shorted

12.44% of the float of REGENXBIO has been sold short.

Short Interest Ratio / Days to Cover

REGENXBIO has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in REGENXBIO has recently decreased by 11.33%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.10

News Sentiment

REGENXBIO has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for REGENXBIO this week, compared to 4 articles on an average week.

Search Interest

4 people have searched for RGNX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, REGENXBIO insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.79% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.08% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RGNX Stock Analysis - Frequently Asked Questions

How have RGNX shares performed this year?

REGENXBIO's stock was trading at $7.73 on January 1st, 2025. Since then, RGNX shares have increased by 18.0% and is now trading at $9.12.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) released its quarterly earnings results on Thursday, August, 7th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.13) by $0.25. The biotechnology company earned $21.36 million during the quarter, compared to analysts' expectations of $40.87 million. REGENXBIO had a negative net margin of 112.70% and a negative trailing twelve-month return on equity of 66.95%.
Read the conference call transcript.

Who are REGENXBIO's major shareholders?

Top institutional investors of REGENXBIO include JPMorgan Chase & Co. (7.63%), Geode Capital Management LLC (2.25%), 22NW LP (1.83%) and Voss Capital LP (1.14%). Insiders that own company stock include Kenneth T Mills, Kenneth T Mills, Curran Simpson, Vittal Vasista, Steve Pakola and Argeris N Karabelas.
View institutional ownership trends.

How do I buy shares of REGENXBIO?

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some other companies that REGENXBIO investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY) and Humana (HUM).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RGNX
• CIK: 1590877
• Web: www.regenxbio.com
• Phone: (240) 552-8181
• Fax: N/A
• Employees: 370
• Year Founded: N/A

Price Target and Rating

• Average Price Target for REGENXBIO: $28.38
• High Price Target: $52.00
• Low Price Target: $12.00
• Potential Upside/Downside: +217.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$227.10 million
• Net Margins: -112.70%
• Pretax Margin: -112.70%
• Return on Equity: -66.95%
• Return on Assets: -34.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.13
• Quick Ratio: 3.13

Sales & Book Value

• Annual Sales: $83.33 million
• Price / Sales: 5.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.23 per share
• Price / Book: 2.11

Miscellaneous

• Outstanding Shares: 50,510,000
• Free Float: 44,053,000
• Market Cap: $451.05 million
• Optionable: Optionable
• Beta: 1.11